Aleksandar Sekulic

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
    Aleksandar Sekulic
    Mayo Clinic, Scottsdale, Arizona Electronic address
    J Am Acad Dermatol 72:1021-6.e8. 2015
  2. doi request reprint Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA
    Curr Opin Oncol 25:218-23. 2013
  3. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
  4. pmc Efficacy and safety of vismodegib in advanced basal-cell carcinoma
    Aleksandar Sekulic
    Mayo Clinic, Scottsdale, AZ 85259, USA
    N Engl J Med 366:2171-9. 2012
  5. doi request reprint Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma
    Aaron R Mangold
    Department of Dermatology, Mayo Clinic, Scottsdale, Arizona Division of Dermatology, LewisGale Hospital Montgomery, Blacksburg, Virginia Section of Biostatistics, Mayo Clinic, Scottsdale, Arizona Department of Surgery, Section of Surgical Oncology, Mayo Clinic, Phoenix, Arizona
    Dermatol Surg 42:646-52. 2016
  6. doi request reprint The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma
    Genevieve L Egnatios
    Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Am J Surg 202:771-7; discussion 777-8. 2011

Detail Information

Publications6

  1. doi request reprint Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC
    Aleksandar Sekulic
    Mayo Clinic, Scottsdale, Arizona Electronic address
    J Am Acad Dermatol 72:1021-6.e8. 2015
    ....
  2. doi request reprint Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA
    Curr Opin Oncol 25:218-23. 2013
    ..This article provides an update on basal cell carcinoma (BCC), with a focus on the advanced BCC (aBCC), and the recent progress with targeted hedgehog signaling pathway inhibition for treatment of aBCC...
  3. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  4. pmc Efficacy and safety of vismodegib in advanced basal-cell carcinoma
    Aleksandar Sekulic
    Mayo Clinic, Scottsdale, AZ 85259, USA
    N Engl J Med 366:2171-9. 2012
    ..A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma...
  5. doi request reprint Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma
    Aaron R Mangold
    Department of Dermatology, Mayo Clinic, Scottsdale, Arizona Division of Dermatology, LewisGale Hospital Montgomery, Blacksburg, Virginia Section of Biostatistics, Mayo Clinic, Scottsdale, Arizona Department of Surgery, Section of Surgical Oncology, Mayo Clinic, Phoenix, Arizona
    Dermatol Surg 42:646-52. 2016
    ..A small percentage of patients will have positive histological margins after primary wide local excision (WLE) of cutaneous melanoma (CM). Risk factors that predict marginal involvement at WLE remain unclear...
  6. doi request reprint The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma
    Genevieve L Egnatios
    Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ, USA
    Am J Surg 202:771-7; discussion 777-8. 2011
    ..Herein, we examine the influence of biopsy technique on residual disease in melanoma WLE specimens and on upstaging...